Анти-VEGF препараты при диабетической ретинопатии

Чехонин Е.С.¹, Павловский О.А.^{1, 2}

Диабетическая ретинопатия – одно из наиболее тяжёлых осложнений сахарного диабета, требующее участия врачей разных специальностей: эндокринологов, диабетологов, терапевтов, кардиологов, хирургов, анестезиологов и других.

Задача офтальмолога – выявить патологические изменения в глазу, связанные с сахарным диабетом, и назначить соответствующее лечение.

Есть три основных метода лечения диабетической ретинопатии:

· лазерная коагуляция сетчатки;

· интравитреальное введение ингибиторов VEGF и глюкокортикоидов;

· хирургическое лечение.

В данном обзоре литературы рассматривается применение ингибиторов эндотелиального фактора роста сосудов при лечении диабетической ретинопатии. В частности, обсуждаются наиболее актуальные лекарственные препараты, важнейшие исследования по терапии ДР и диабетического макулярного отёка, а также post hoc анализ этих исследований. Также обсуждается роль этих препаратов в терапии рефрактерного ДМО. Также затрагиваются будущие стратегии терапии и значение лекарственных препаратов для профилактики развития ДР и ДМО.

1. Роль блокады ангиогенеза у пациентов с диабетической ретинопатией / Е. С. Чехонин, Р. Р. Файзрахманов, М. М. Шишкин, М. Р. Каланов // Офтальмохирургия. – 2022. – № 4. – С. 85-91. – DOI 10.25276/0235-4160-2022-4-85-91.

2. Анти-VEGF препараты в лечении диабетической ретинопатии / Е. С. Чехонин, Р. Р. Файзрахманов, А. В. Суханова, Э. Д. Босов // Вестник офтальмологии. – 2021. – Т. 137, № 4. – С. 136-142. – DOI 10.17116/oftalma2021137041136.

3. Чехонин, Е. С. Анти-VEGF при диабетической ретинопатии: новые перспективы / Е. С. Чехонин // Вестник Национального медико-хирургического центра им. Н.И. Пирогова. – 2022. – Т. 17, № S4. – С. 54-56. – DOI 10.25881/20728255_2022_17_4_S1_54.

4. Современное представление о неоваскулярной глаукоме (обзор) / Р. Р. Файзрахманов, М. Е. Калинин, О. А. Павловский [и др.] // Офтальмологические ведомости. – 2023. – Т. 16, № 3. – С. 99-108. – DOI 10.17816/OV490823.

5. Изменение толщины центральной зоны сетчатки после витрэктомии по поводу регматогенной отслойки сетчатки с использованием силиконовой тампонады / Р. Р. Файзрахманов, А. В. Суханова, О. А. Павловский [и др.] // Вестник Национального медико-хирургического центра им. Н.И. Пирогова. – 2020. – Т. 15, № 2. – С. 89-91. – DOI 10.25881/BPNMSC.2020.32.27.015.

6. Uehara F, Ohba N, Ozawa M. Isolation and characterization of galectins in the mammalian retina. Invest Ophthalmol Vis Sci. 2001;42(10):2164-2172.

7. Kanda A, Noda K, Saito W, et al. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Sci Rep. 2015;5:17946. https://doi.org/10.1038/srep17946

8. Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M, Rabinovich GA. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014;156(4):744-758. https:// doi.org/10.1016/j.cell.2014.01.043

9. Yule Xu, Ao Rong, Yanlong Bi, Wei Xu. Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice. J Ophthalmol. 2016; 2016:2143082. https://doi.org/10.1155/2016/2143082

10. Tadayoni R, Sararols L, Weissgerber G. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93-101. https://doi.org/ 10.1159/000513048

11. Corradetti G, Corvi F, Nguyen TV, Sadda SR. Management of Neovascular Age-Related Macular Degeneration during the COVID-19 Pandemic. Ophthalmol Retina. 2020;4(8):757-759. https://doi.org/10.1016/j.ophtha. 2019.12.031

12. Dugel PU. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021;128(1):89-99. https://doi.org/10.1016/j. ophtha.2020.06.028

13. Brown D, Wolf S, Garweg JG, et al. Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KESTREL & KITE studies, May 1—7, 2021, ARVO, Poster.

14. Heier, J.S.; Khanani, A.M.; Quezada Ruiz, C.; Basu, K.; Ferrone, P.J.; Brittain, C.; Figueroa, M.S.; Lin, H.; Holz, F.G.; Patel, V.; et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet 2022, 399, 729–740.

15. Wykoff, C.C.; Abreu, F.; Adamis, A.P.; Basu, K.; Eichenbaum, D.A.; Haskova, Z.; Lin, H.; Loewenstein, A.; Mohan, S.; Pearce, I.A.; et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials. Lancet 2022, 399, 741–755.

16. Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, Scott LC. Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1). Clin Ophthalmol. 2017;11:393-401. https://doi.org/10.2147/OPTH.S128509

17. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016; 123(6):1351-1359. https://doi.org/10.1016/j.ophtha.2016.02.022

18. Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, Grover S, Jampol LM, Jhaveri CD, Melia M, Stockdale CR, Martin DF, Sun JK; DRCR Retina Network. Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial. JAMA. 2019;321(19):1880-1894. https://doi.org/10.1001/jama.2019.5790

19. Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol I study data. Retina. 2019;39(1):88-97. https://doi.org/10.1097/ IAE.0000000000002110

20. Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA; Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017;135(6):558-568. https://doi.org/10.1001/jamaophthalmol.2017.0821

21. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145-1152. https://doi.org/10.1001/archophthalmol.2012.1043

22. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015;122(2):367-374. https://doi.org/10.1016/j.ophtha.2014.08.048

23. Wykoff CC. Intravitreal aflibercept for moderately severe to severe nonproliferative diabetic retinopathy (NPDR): the Phase III PANORAMA Study. American Society of Retina Specialists Annual Meeting; 2018, Vancouver, Canada.

24. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376-2385. https://doi.org/10.1016/ j.ophtha.2016.07.032

25. Sugimoto M, Ichio A, Mochida D, et al. Multiple effects of intravitreal aflibercept on microvascular regression in eyes with diabetic macular edema. Ophthalmol Retina. 2019;3:1067-1075. https://doi.org/10.1016/j.oret.2019.06.005

26. Wykoff CC, Shah C, Dhoot D, et al. Longitudinal retinal perfusion status in eyes with diabetic macular edema receiving intravitreal aflibercept or laser in VISTA study. Ophthalmology. 2019;126(8):1171-1180. https://doi.org/10.1016/j.ophtha.2019.03.040

27. MJ E. To treat or not to treat: are we sacrificing treatment outcomes by allowing diabetic retinopathy (DR) to enter the proliferative stage? American Society of Retina Specialists Annual Meeting; 2018, Vancouver, Canada.

28. Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net protocol T. Curr Opin Ophthalmol. 2017;28(6):636-643. https://doi.org/10.1097/ICU.0000000000000424

29. Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Costeffectiveness of treatment of diabetic macular edema. Ann Intern Med. 2014;160(1):18-29. https://doi.org/10.7326/M13-0768

30. Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular-thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for center-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257-269. https://doi.org/10.1001/jamaophthalmol.2017.6565

31. Dugel PU, Layton A, Varma RB. Diabetic macular edema diagnosis and treatment in the real world: an analysis of medicare claims data (2008 to 2010). Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):258-267. https://doi.org/10.3928/23258160-20160229-09

32. Bolinger MT, Antonetti DA. Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. Int J Mol Sci. 2016;17(9):1498. https://doi.org/10.3390/ijms17091498

33. Spencer DB, Protopsaltis NJ, Chao DL. New pharmacotherapies for diabetic retinopathy. Ann Eye Sci. 2018;3(43):1-13. https://doi.org/10.21037/aes.2018.08.02

34. Stewart MW. Future treatments of diabetic retinopathy: pharmacotherapeutic products under development. Eur Med J Diabetes. 2017;5(1):93-103.

35. Bahrami B, Zhu M, Hong T, Chang A. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia. 2016;59(8):1594-1608. https://doi.org/10.1007/s00125-016-3974-8

36. Dhoot DS, Pieramici DJ, Nasir M, Castellarin AA, Couvillion S, See RF, Steinle N, Bennett M, Rabena M, Avery RL. Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye (Lond). 2015;29(4):534-541. https://doi.org/10.1038/eye.2014.338

37. Ciulla TA, Hussain RM, Ciulla LM, Sink B, Harris A. Ranibizumab for diabetic macular edema refractory to multiple prior treatments. Retina. 2016; 36(7):1292-1297. https://doi.org/10.1097/IAE.0000000000000876

38. Hanhart J, Chowers I. Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema. Case Rep Ophthalmol. 2015;6(1):44-50. https://doi.org/10.1159/000375230

39. Ashraf M, Souka AA, ElKayal H. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases with Non-Response to Bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017; 48(3):230-236. https://doi.org/10.3928/23258160-20170301-06